Daewoong’s Enblo Demonstrates Strong Potential to Reverse Fatty Liver in Diabetes Patients
Daewoong Pharmaceutical announced that its newly developed type 2 diabetes medication, Enblo (active ingredient: inavogliflozin), has shown...
Search results for "Enblo"
Daewoong Pharmaceutical Secures 145.2 Billion Won MENA Export Deal for Diabetes Drug Enblo
Daewoong Pharmaceutical’s proprietary type 2 diabetes treatment, Enblo (active ingredient: enavogliflozin), is set to enter eight major markets in...
Mexico Greenlights Daewoong’s Envlo, Fueling Latin American Expansion
Daewoong Pharmaceutical announced on May 27 that its type 2 diabetes treatment, Envlo 0.
K-Pharma Sets Sights on Veterinary Market: Daewoong Pharmaceutical Leads the Charge
More than 10 South Korean pharmaceutical companies are pivoting toward veterinary medicine as a strategic growth engine.
1